CLINICAL TRIALS PROFILE FOR DEPACON
✉ Email this page to a colleague
All Clinical Trials for DEPACON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000439 ↗ | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | University of Pittsburgh | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00000439 ↗ | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00203242 ↗ | An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches. | Completed | Abbott | N/A | 2003-07-01 | The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first. |
| NCT00203242 ↗ | An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches. | Completed | Thomas Jefferson University | N/A | 2003-07-01 | The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first. |
| NCT00609245 ↗ | Effect of Valproic Acid Concentration on Photic Response | Completed | Abbott | Phase 4 | 2007-12-01 | We are trying to learn if small changes in the amount of a valproate in the blood (given through an IV) will change the way the brain reacts to flashing lights. |
| NCT00609245 ↗ | Effect of Valproic Acid Concentration on Photic Response | Completed | Vanderbilt University Medical Center | Phase 4 | 2007-12-01 | We are trying to learn if small changes in the amount of a valproate in the blood (given through an IV) will change the way the brain reacts to flashing lights. |
| NCT01951560 ↗ | A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) | Completed | Dr. Hasan Alam | Phase 1 | 2013-09-01 | The purpose of the first part of this study is to determine the safety and tolerability of ascending doses of valproic acid (also known as Depacon) administered as intravenous infusion (IV) in doses ranging from 15 mg/kg to 250 mg/kg in healthy subjects. The second part of the study will also be to determine the safety and tolerability of single ascending doses of valproic acid administered as IV in trauma subjects with hemorrhagic shock. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DEPACON
Condition Name
Clinical Trial Locations for DEPACON
Trials by Country
Clinical Trial Progress for DEPACON
Clinical Trial Phase
Clinical Trial Sponsors for DEPACON
Sponsor Name
